Internal Medicine, Rheumatology · Neptune, NJ
NPI
1124150834
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
19 Davis Ave Fl 6
Neptune, NJ, 07753
Phone (732) 897-3985
Groups this clinician bills Medicare through
Medicare paid, 2024
$322K
46,523 services
Medicare patients, 2024
355
Average age 74
Drug cost, 2024
$1.8M
1,415 prescriptions
Company payments, 2025
$5,522
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Deborah R Alpert was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 31,200 times for 20 patients. In total Deborah R Alpert billed 46,523 services in 30 codes, and Medicare paid $322K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-27.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 31,200 | 20 | $3.61 | $113K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 7,980 | 14 | $8.63 | $69K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 3,241 | 42 | $0.10 | $331 |
| J0897 Injection, denosumab, 1 mg | Office | 2,340 | 32 | $20.68 | $48K |
| 99214 Office E&M - Established | Office | 356 | 210 | $101.53 | $36K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 336 | 210 | $13.30 | $4,468 |
| 96372 Injection Administration | Office | 229 | 87 | $11.87 | $2,717 |
| 99215 Office E&M - Established | Office | 65 | 46 | $145.45 | $9,454 |
| 99213 Office E&M - Established | Office | 61 | 52 | $70.49 | $4,300 |
| 99232 Hospital E&M - Subsequent | Facility | 50 | 27 | $64.90 | $3,245 |
| 99222 Hospital E&M - Initial | Facility | 38 | 36 | $106.72 | $4,055 |
| 99204 Office E&M - New | Office | 32 | 32 | $123.92 | $3,965 |
| 20600 Joint Injection | Office | 20 | 14 | $42.05 | $841 |
| 20610 Joint Injection | Office | 18 | 14 | $55.91 | $1,006 |
| 99231 Hospital E&M - Subsequent | Facility | 15 | 12 | $41.69 | $625 |
By year: 2022 $181K for 19,662 services; 2023 $287K for 38,588 services; 2024 $322K for 46,523 services.
Medicare prescription drug claims, 2024
In 2024, the drug Deborah R Alpert prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 250 prescriptions and refills. In total Deborah R Alpert wrote 1,415 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 250 | 691 | 82 | $12K |
| Methotrexate Methotrexate Sodium | 183 | 418 | 59 | $5,632 |
| Prednisone Generic | 100 | 239 | 39 | $1,222 |
| Duloxetine Hcl Generic | 74 | 210 | 25 | $1,895 |
| Allopurinol Generic | 74 | 190 | 26 | $1,017 |
| Celecoxib Generic | 50 | 138 | 19 | $2,223 |
| Otezla Apremilast | 45 | 47 | Under 11 | $176K |
| Meloxicam Generic | 38 | 99 | 21 | $129 |
| Rinvoq Upadacitinib | 37 | 46 | Under 11 | $291K |
| Leflunomide Generic | 33 | 69 | Under 11 | $1,147 |
| Cyclobenzaprine Hcl Generic | 32 | 78 | 15 | $401 |
| Orencia Clickject Abatacept | 29 | 35 | Under 11 | $201K |
| Folic Acid Generic | 27 | 75 | Under 11 | $402 |
| Sulfasalazine Generic | 25 | 61 | Under 11 | $999 |
| Amitriptyline Hcl Generic | 25 | 75 | Under 11 | $583 |
Brand drugs: - claims; generic drugs: 1,137 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Deborah R Alpert $5,522 ($5,522 in general payments such as food, travel and fees) from 16 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $4,392.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $4,392 |
| Abbvie Inc. ABBV | 15 | $353 |
| GlaxoSmithKline, LLC. GSK | 6 | $199 |
| Janssen Biotech, Inc. JNJ | 5 | $149 |
| Amgen Inc. AMGN | 5 | $85.54 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $61.96 |
| ViiV Healthcare Company GSK | 3 | $55.91 |
| Corcept Therapeutics CORT | 3 | $52.25 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $36.34 |
| Merck Sharp & Dohme LLC MRK | 2 | $28.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.